HomeIOVA • NASDAQ
add
Iovance Biotherapeutics Inc
Previous close
$11.54
Day range
$11.34 - $11.80
Year range
$3.21 - $18.33
Market cap
3.25B USD
Avg Volume
5.16M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Top news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 482.00K | — |
Operating expense | 117.37M | 9.66% |
Net income | -116.38M | -10.50% |
Net profit margin | -24.15K | — |
Earnings per share | -0.45 | 29.69% |
EBITDA | -118.62M | -13.81% |
Effective tax rate | 1.49% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 279.87M | -40.69% |
Total assets | 780.35M | 17.53% |
Total liabilities | 195.74M | 19.10% |
Total equity | 584.61M | — |
Shares outstanding | 279.31M | — |
Price to book | 5.06 | — |
Return on assets | -37.13% | — |
Return on capital | -42.88% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -116.38M | -10.50% |
Cash from operations | -83.97M | -8.11% |
Cash from investing | -72.84M | -15,901.52% |
Cash from financing | 962.00K | -99.50% |
Net change in cash | -152.83M | -234.81% |
Free cash flow | -39.93M | -12.67% |
About
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte therapies against cancer. Wikipedia
Founded
2007
Headquarters
Website
Employees
557